Jordi Xaus

Dr. Xaus holds a degree in Biology (1995) and a master's degree in Immunology (1997) both from the University of Barcelona. He received his doctorate in Biology from the University of Barcelona (1999) in the field of the immune response control. He has completed his scientific training with pre and postdoctoral stays at La Jolla Cancer Research Foundation / The Burnham Institute (San Diego, USA, 1996) and at Genentech Inc (San Francisco, USA, 1999-2000). Author of almost a hundred of scientific publications and ten patents. Director of six doctoral theses.

He was Associate Professor of Immunology at the University of Barcelona until 2001, before joining the biotechnology industry. Initially, at Puleva Biotech SA as head of the Immunology Department where, among other projects, he led the discovery and development of the Hereditum® probiotic product line, and years later he became Director of Biomedicine and member of the Board of Directors. In 2007 he joined the biopharmaceutical Palau Pharma SA and in 2012 was nominated CSO. During this period, he participated in the licensing and sale of four Company’ compounds to third party’ pharmaceutical companies.

In 2014, he joined Oryzon Genomics where he held various management positions and contributed to the clinical transition of the epigenetic molecules iadademstat and vafidemstat, both currently in Phase II in oncology and CNS disorders respectively.

In January 2020, he was appointed Director of the Clinical Portfolio and Innovation of the company.

Since July 2021 he is Chief Scientific Officer of Oryzon Genomics.

His training is complemented by the completion of the Executive Master in Operations and Innovation (EMOI) at ESADE Business School (2019).